Recent Security Class Actions

Gossamer Bio Inc. Common Stock (NASDAQ: GOSS)

41 Days left to seek lead plaintiff status.

Company Name:Gossamer Bio Inc. Common Stock
Stock Symbol:NASDAQ: GOSS
Class Period Start:06/16/2025
Class Period End (inclusive):02/20/2026
Filing Deadline:06/01/2026

The complaint alleges defendants provided investors with material information concerning Gossamer’s Phase 3 PROSERA study evaluating seralutinib for the treatment of pulmonary arterial hypertension (PAH). Defendants’ statements included, among other things, confidence in PROSERA’s trial design. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the study design for the Company’s Phase 3 PROSERA study, particularly, controlling for the placebo response at the Latin American testing sites. This caused Plaintiff and other shareholders to purchase Gossamer’s securities at artificially inflated prices.

Gossamer Bio Inc. Common Stock (NASDAQ: GOSS) Claim Form

This field is for validation purposes and should be left unchanged.
Name(Required)
Address